Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.63 |
| ▸ | RXRA | P19793 | 5/20 | 0.63 |
| ▸ | RARA | P10276 | 4/20 | 0.63 |
| ▸ | RARB | P10826 | 4/20 | 0.63 |
| ▸ | RARG | P13631 | 4/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.63 |
| ▸ | APP | P05067 | 4/20 | 0.63 |
| ▸ | SNCA | P37840 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.63 |
| ▸ | RXRB | P28702 | 2/20 | 0.63 |
| ▸ | RXRG | P48443 | 2/20 | 0.63 |
| ▸ | RORC | P51449 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006702 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL1895263 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2008326 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL57568 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL1695153 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL3422972 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL4399478 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2005744 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2005804 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2008700 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429972-B1 | DUAL-UNIT PACK | UNILEVER IP HOLDINGS B V (NL) | 2025-04-23 | — | — | EP | claimed |
| EP-4429972-A1 | DUAL-UNIT PACK | Unilever IP Holdings B.V. (NL) | 2024-09-18 | — | — | EP | claimed |
| CN-118251350-A | Double unit package | 联合利华知识产权控股有限公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2023083683-A1 | DUAL-UNIT PACK | UNILEVER IP HOLDINGS B.V. (NL) | 2023-05-19 | — | — | WO | claimed |
| US-20080287393-A1 | External Skin Composition | KAO CORPORATION (JP) | 2008-11-20 | — | — | US | claimed |
| WO-2006079209-A1 | PULMONARY COMPOSITIONS COMPRISING A VITAMIN A COMPOUND AND A SURFACTANT AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2006-08-03 | — | — | WO | claimed |
| EP-1342471-B1 | Nanocapsules based on polyol polyester, and cosmetic and dermatological compositions containing same | OREAL (FR) | 2005-06-08 | — | — | EP | claimed |
| US-20050002879-A1 | External skin compositions | KAO CORPORATION (JP) | 2005-01-06 | — | — | US | claimed |
| US-20030224060-A1 | Polyester polyol nanocapsules, compositions thereof, and methods of use | L'OREAL (FR) | 2003-12-04 | — | — | US | claimed |
| US-20030215413-A1 | Compositions containing stabilized retinoid | L'OREAL (FR) | 2003-11-20 | — | — | US | claimed |
| US-6451330-B1 | DIMINISHES THE APPEARANCE AND FEEL OF OILY SKIN AND IS CAPABLE OF DELIVERING BENEFITS ASSOCIATED WITH RETINOIDS | UNILEVER HOME & PERSONAL CARE, USA, DIVISION OF CONOPCO, INC. | 2002-09-17 | — | — | US | claimed |
| WO-2026098831-A1 | USE OF A PERSONAL CARE COMPOSITION FOR IMPROVING THE BARRIER FUNCTION OF SKIN | UNILEVER IP HOLDINGS B.V. (NL) | 2026-05-15 | — | — | WO | disclosed |
| EP-4351513-B1 | SKIN CARE COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026041386-A1 | ANHYDROUS COMPOSITION COMPRISING MONOESTERS AND MAINLY PETROLATUM | UNILEVER IP HOLDINGS B.V. (NL) | 2026-02-26 | — | — | WO | disclosed |
| US-12485071-B2 | Personal care composition with visually distinct aqueous and oil phase | CONOPCO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-5665367-A | Skin care compositions containing naringenin and/or quercetin and a retinoid | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5599548-A | REDUCING OR PREVENTING THE APPEARANCE OF WRINKLED OR AGED SKIN | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0745375-A1 | Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester | UNILEVER PLC (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0742005-A2 | Skin care compositions containing fatty acid amides and retinol or retinyl ester | UNILEVER PLC (GB) | 1996-11-13 | — | — | EP | disclosed |
| US-5536740-A | Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester | ELIZABETH ARDEN COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030215413-A1 | Compositions containing stabilized retinoid | RARA, RARB, RARG | ALDH1A1 450/4885ADORA3 1093/4885MAPT 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.